Completed PHASE3 INTERVENTIONAL 4-arm NCT01797081

BOTOX® in the Treatment of Crow's Feet Lines in Japan

Sponsor: Allergan

Conditions Crow's Feet Lines Lateral Canthus Rhytides

Interventions Normal Saline botulinum toxin Type A (12 U) botulinum toxin Type A (24 U)

Updated 7 times since 2017 Last updated: Apr 3, 2019 Started: Jan 31, 2013 Primary completion: Jul 18, 2013 Completion: Jul 7, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Crow's Feet Lines and Lateral Canthus Rhytides and is currently completed. Allergan leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — May 2019 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan